Safety of megestrol acetate in palliating anorexia-cachexia syndrome in patients with castration-resistant prostate cancer.

about

Safety of megestrol acetate in palliating anorexia-cachexia syndrome in patients with castration-resistant prostate cancer.

Item

http://www.wikidata.org/entity/Q36841080

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Safety of megestrol acetate in ...... ion-resistant prostate cancer.

@en

type

Item

label

Safety of megestrol acetate in ...... ion-resistant prostate cancer.

@en

prefLabel

Safety of megestrol acetate in ...... ion-resistant prostate cancer.

@en

P1476

Safety of megestrol acetate in ...... ion-resistant prostate cancer.

@en

P2093

Choung-Soo Kim

http://www.w3.org/2001/XMLSchema#string

Dalsan You

http://www.w3.org/2001/XMLSchema#string

Hanjong Ahn

http://www.w3.org/2001/XMLSchema#string

In Gab Jeong

http://www.w3.org/2001/XMLSchema#string

Jae-Lyun Lee

http://www.w3.org/2001/XMLSchema#string

Jun Hyuk Hong

http://www.w3.org/2001/XMLSchema#string

Sungwoo Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Megestrol acetate in relapsed carcinoma of prostate.

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

ABC of palliative care. Anorexia, cachexia, and nutrition.

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Clinical significance of free-to-total prostate-specific antigen (PSA) ratio in advanced prostate cancer patients with PSA less than 0.1 ng/ml after hormone treatment

Prediction of cancer incidence and mortality in Korea, 2012

P304

687-692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3346/JKMS.2013.28.5.687

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236912882

http://www.w3.org/2001/XMLSchema#string

P698

23678259

http://www.w3.org/2001/XMLSchema#string

P932

3653080

http://www.w3.org/2001/XMLSchema#string